Arca
Skip to content
Tools
Tools

Spondylitis

Drug research and approvals for spondylitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 153 studies of spondylitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 153
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 0
  • EU medicines: 6

Recruiting now

Newest posted first, of 153 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 9

How its trials ended

718 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 183 whose ending is known, 63% met their primary endpoint, 8% missed it and 30% stopped early.

  • Completed, result not reported26737%
  • Ongoing15421%
  • Met its primary endpoint11516%
  • Status unknown11416%
  • Stopped: other or unclear274%
  • Stopped: enrollment or feasibility152%
  • Missed its primary endpoint142%
  • Stopped: lack of efficacy61%
  • Stopped: sponsor or business decision41%
  • Stopped: safety2<1%

Trials authorized in Canada

The 10 newest of 13; search them all in Canada trials
Aug 13, 2025A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with radiographic axial…Tulisokibart (MK-7240)Merck & Co. (MSD)Ongoing
Sep 3, 2021A phase 2 multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CC-99677 in subjects with…BMS-986371 (CC-99677)Bristol-Myers SquibbClosed
Aug 31, 2020A phase 3, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of filgotinib in subjects with active ankylosing spondylitis…FilgotinibGilead SciencesClosed
Aug 31, 2020A phase 3, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of filgotinib in subjects with active ankylosing spondylitis…FilgotinibGilead SciencesClosed
Apr 23, 2018A phase 3, randomized, double-blind, placebo-controlled, study of the efficacy and safety of tofacitinib in subjects with active ankylosing spondylitis (AS)Tofacitinib (CP-690,550)PfizerClosed
Nov 14, 2017A multicenter, open-label, extension study to evaluate the long term safety and efficacy of bimekizumab in subjects with ankylosing spondylitisBimekizumabUCBOngoing
Nov 10, 2017A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017…Cosentyx / GP2017 (adalimumab)Novartis PharmaceuticalsClosed
Aug 14, 2017A multicenter, randomized, double-blind, placebo controlled study evaluating the safety and efficacy of upadacitinib in subjects with active ankylosing…Upadacitinib (ABT-494)AbbVieClosed
Nov 23, 2016A multicenter, phase 2b, randomized, double blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of bimekizumab in…BimekizumabUCBOngoing
Feb 13, 2015A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading…Secukinumab (AIN457)Novartis PharmaceuticalsOngoing

Medicines authorised in the EU

Newest first
Jul 26, 2018HefiyaAdalimumab · biosimilarSandoz GmbHEMA ↗
May 18, 2018ZesslyInfliximab · biosimilarSandoz GmbHEMA ↗
Aug 24, 2017ImraldiAdalimumab · biosimilarSamsung Bioepis NL B.V.EMA ↗
Sep 8, 2003HumiraAdalimumabAbbVie Deutschland GmbH & Co. KGEMA ↗
Feb 2, 2000EnbrelEtanerceptPfizer Europe MA EEIGEMA ↗
Aug 13, 1999RemicadeInfliximabJanssen Cilag International NVEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.